Class information for:
Level 1: HIV VACCINE//MOL MUCOSAL VACCINE IMMUNOL GRP//HIV VACCINE TRIALS NETWORK

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
12424 906 49.3 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
29 3       HIV//VIROLOGY//HIV 1 108954
10 2             AIDS RESEARCH AND HUMAN RETROVIRUSES//VIROLOGY//HIV 1 39664
12424 1                   HIV VACCINE//MOL MUCOSAL VACCINE IMMUNOL GRP//HIV VACCINE TRIALS NETWORK 906

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 HIV VACCINE authKW 434231 7% 20% 66
2 MOL MUCOSAL VACCINE IMMUNOL GRP address 209984 1% 69% 9
3 HIV VACCINE TRIALS NETWORK address 176054 2% 33% 16
4 VACCINE address 148101 11% 4% 104
5 VACCINE BRANCH address 145822 4% 12% 35
6 STEP TRIAL authKW 140423 1% 83% 5
7 MOL IMMUNOGENET VACCINE SECT address 137156 2% 24% 17
8 PRIME BOOST authKW 128586 3% 14% 27
9 CHIMPANZEE ADENOVIRUS authKW 107845 0% 80% 4
10 AD5 IMMUNITY authKW 101106 0% 100% 3

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Virology 15772 32% 0% 288
2 Immunology 13019 57% 0% 516
3 Medicine, Research & Experimental 4406 26% 0% 240
4 Infectious Diseases 3098 18% 0% 162
5 Biotechnology & Applied Microbiology 326 9% 0% 85
6 Microbiology 209 8% 0% 70
7 Genetics & Heredity 38 4% 0% 38
8 Multidisciplinary Sciences 17 1% 0% 9
9 Biochemical Research Methods 14 2% 0% 21
10 Mathematical & Computational Biology 5 1% 0% 7

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MOL MUCOSAL VACCINE IMMUNOL GRP 209984 1% 69% 9
2 HIV VACCINE TRIALS NETWORK 176054 2% 33% 16
3 VACCINE 148101 11% 4% 104
4 VACCINE BRANCH 145822 4% 12% 35
5 MOL IMMUNOGENET VACCINE SECT 137156 2% 24% 17
6 IAVI CORE 89869 0% 67% 4
7 KAVI 75828 0% 75% 3
8 MEDUNSA HIV CLIN UNIT 75828 0% 75% 3
9 CORE OPERAT 67404 0% 100% 2
10 VACCINE PHARMACEUT DEV 67404 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 VACCINE 38756 16% 1% 144
2 CURRENT OPINION IN HIV AND AIDS 17866 2% 3% 21
3 JOURNAL OF VIROLOGY 9854 12% 0% 108
4 EXPERT REVIEW OF VACCINES 8749 2% 1% 18
5 AIDS RESEARCH AND HUMAN RETROVIRUSES 6018 3% 1% 31
6 MUCOSAL IMMUNOLOGY 3425 1% 1% 9
7 CLINICAL AND VACCINE IMMUNOLOGY 2489 2% 1% 14
8 HUMAN VACCINES & IMMUNOTHERAPEUTICS 2398 1% 1% 11
9 CURRENT HIV RESEARCH 2000 1% 1% 7
10 VIRAL IMMUNOLOGY 1875 1% 1% 8

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 HIV VACCINE 434231 7% 20% 66 Search HIV+VACCINE Search HIV+VACCINE
2 STEP TRIAL 140423 1% 83% 5 Search STEP+TRIAL Search STEP+TRIAL
3 PRIME BOOST 128586 3% 14% 27 Search PRIME+BOOST Search PRIME+BOOST
4 CHIMPANZEE ADENOVIRUS 107845 0% 80% 4 Search CHIMPANZEE+ADENOVIRUS Search CHIMPANZEE+ADENOVIRUS
5 AD5 IMMUNITY 101106 0% 100% 3 Search AD5+IMMUNITY Search AD5+IMMUNITY
6 ADENOVIRUS 26 101106 0% 100% 3 Search ADENOVIRUS+26 Search ADENOVIRUS+26
7 POXVIRUS VECTORS 101100 1% 50% 6 Search POXVIRUS+VECTORS Search POXVIRUS+VECTORS
8 NYVAC 77030 0% 57% 4 Search NYVAC Search NYVAC
9 RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA 75828 0% 75% 3 Search RECOMBINANT+MODIFIED+VACCINIA+VIRUS+ANKARA Search RECOMBINANT+MODIFIED+VACCINIA+VIRUS+ANKARA
10 MVA 74250 2% 12% 18 Search MVA Search MVA

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 ONDONDO, BO , (2014) THE INFLUENCE OF DELIVERY VECTORS ON HIV VACCINE EFFICACY.FRONTIERS IN MICROBIOLOGY. VOL. 5. ISSUE . P. - 95 33% 11
2 EXCLER, JL , TOMARAS, GD , RUSSELL, ND , (2013) NOVEL DIRECTIONS IN HIV-1 VACCINES REVEALED FROM CLINICAL TRIALS.CURRENT OPINION IN HIV AND AIDS. VOL. 8. ISSUE 5. P. 421-431 56 47% 14
3 GRAY, GE , MOODIE, Z , METCH, B , GILBERT, PB , BEKKER, LG , CHURCHYARD, G , NCHABELENG, M , MLISANA, K , LAHER, F , ROUX, S , ET AL (2014) RECOMBINANT ADENOVIRUS TYPE 5 HIV GAG/POL/NEF VACCINE IN SOUTH AFRICA: UNBLINDED, LONG-TERM FOLLOW-UP OF THE PHASE 2H HVTN 503/PHAMBILI STUDY.LANCET INFECTIOUS DISEASES. VOL. 14. ISSUE 5. P. 388-396 27 79% 33
4 GOMEZ, CE , PERDIGUERO, B , GARCIA-ARRIAZA, J , ESTEBAN, M , (2012) POXVIRUS VECTORS AS HIV/AIDS VACCINES IN HUMANS.HUMAN VACCINES & IMMUNOTHERAPEUTICS. VOL. 8. ISSUE 9. P. 1192-1207 54 49% 14
5 PARIS, RM , KIM, JH , ROBB, ML , MICHAEL, NL , (2010) PRIME-BOOST IMMUNIZATION WITH POXVIRUS OR ADENOVIRUS VECTORS AS A STRATEGY TO DEVELOP A PROTECTIVE VACCINE FOR HIV-1.EXPERT REVIEW OF VACCINES. VOL. 9. ISSUE 9. P. 1055-1069 58 45% 39
6 BADEN, LR , LIU, JY , LI, HL , JOHNSON, JA , WALSH, SR , KLEINJAN, JA , ENGELSON, BA , PETER, L , ABBINK, P , MILNER, DA , ET AL (2015) INDUCTION OF HIV-1-SPECIFIC MUCOSAL IMMUNE RESPONSES FOLLOWING INTRAMUSCULAR RECOMBINANT ADENOVIRUS SEROTYPE 26 HIV-1 VACCINATION OF HUMANS.JOURNAL OF INFECTIOUS DISEASES. VOL. 211. ISSUE 4. P. 518 -528 23 82% 12
7 ZHANG, SJ , HUANG, WX , ZHOU, XY , ZHAO, QQ , WANG, Q , JIA, B , (2013) SEROPREVALENCE OF NEUTRALIZING ANTIBODIES TO HUMAN ADENOVIRUSES TYPE-5 AND TYPE-26 AND CHIMPANZEE ADENOVIRUS TYPE-68 IN HEALTHY CHINESE ADULTS.JOURNAL OF MEDICAL VIROLOGY. VOL. 85. ISSUE 6. P. 1077-1084 31 63% 12
8 O'CONNELL, RJ , KIM, JH , COREY, L , MICHAEL, NL , (2012) HUMAN IMMUNODEFICIENCY VIRUS VACCINE TRIALS.COLD SPRING HARBOR PERSPECTIVES IN MEDICINE. VOL. 2. ISSUE 12. P. - 55 35% 26
9 HAYES, P , GILMOUR, J , VON LIEVEN, A , GILL, D , CLARK, L , KOPYCINSKI, J , CHEESEMAN, H , CHUNG, A , ALTER, G , DALLY, L , ET AL (2013) SAFETY AND IMMUNOGENICITY OF DNA PRIME AND MODIFIED VACCINIA ANKARA VIRUS-HIV SUBTYPE C VACCINE BOOST IN HEALTHY ADULTS.CLINICAL AND VACCINE IMMUNOLOGY. VOL. 20. ISSUE 3. P. 397 -408 32 57% 9
10 SANTRA, S , SUN, Y , KORIOTH-SCHMITZ, B , FITZGERALD, J , CHARBONNEAU, C , SANTOS, G , SEAMAN, MS , RATCLIFFE, SJ , MONTEFLORI, DC , NABEL, GJ , ET AL (2009) HETEROLOGOUS PRIME/BOOST IMMUNIZATIONS OF RHESUS MONKEYS USING CHIMPANZEE ADENOVIRUS VECTORS.VACCINE. VOL. 27. ISSUE 42. P. 5837-5845 25 78% 28

Classes with closest relation at Level 1


Rank Class id link
1 1456 PARTNERS AIDS//DORIS DUKE MED//HIV PATHOGENESIS PROGRAMME
2 758 IAVI NEUTRALIZING ANTIBODY//DUKE HUMAN VACCINE//HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER
3 3573 DNA VACCINE//DNA IMMUNIZATION//DNA VACCINATION
4 34386 MOL BIOL VIRAL ONCOGENESIS//HYPERVARIABLE EPITOPE CONSTRUCTS//LENTIVIRAL VLP
5 3332 SIV//SHIV//SIMIAN IMMUNODEFICIENCY VIRUS
6 20980 EXPOSED UNINFECTED//HESN//HIV EXPOSED SERONEGATIVE
7 16785 HIV VACCINE TRIALS//HIV VACCINE//WILLINGNESS TO PARTICIPATE
8 3599 ADENOVIRUS//COXSACKIE ADENOVIRUS RECEPTOR//HUMAN GENE THER Y
9 21810 ELISPOT//FLUOROSPOT//DUAL COLOR ENZYME LINKED IMMUNOSPOT ELISPOT ASSAY
10 6997 MOL MED GENE THER Y UNIT//ADENOVIRUS//HELPER DEPENDENT ADENOVIRAL VECTOR

Go to start page